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ABSTRACT: Avoiding unwanted immunogenicity is of key importance in the development
of therapeutic drug proteins. Animal models are of less predictive value because most of the
drug proteins are recognized as foreign proteins. However, different methods have been de-
veloped to obtain immunotolerant animal models. So far, the immunotolerant animal models
have been developed to assess one protein at a time and are not suitable for the assessment
of combination products. Our aim was to develop an animal model for evaluating the im-
pact of manufacturing and formulation changes on immunogenicity, suitable for both single
protein and combination products. We constructed two lines of transgenic mice expressing the
three human coagulation factors, II, VII, and X, by inserting a single vector containing the
three coagulation factors encoding sequences separated by insulator sequences derived from
the chicken beta-globin locus into the mouse genome. Immunization of transgenic mice from
the two lines and their wild-type littermates showed that transgenic mice from both lines
were immunotolerant to the expressed human coagulation factors. We conclude that trans-
genic mice immunotolerant to multiple proteins can be obtained, and that these mice are
potentially useful as animal models in the assessment of immunogenicity in response to man-
ufacturing changes. © 2013 Wiley Periodicals, Inc. and the American Pharmacists Association
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INTRODUCTION
During the development of therapeutic proteins, one
of the most important aspects that needs to be ad-
dressed is their potential immunogenicity. Treatment
with therapeutic proteins having a nonredundant en-
dogenous counterpart could potentially trigger an im-
munological response leading to neutralization of the
endogenous proteins and adverse events. Predicting
risks for immunogenicity is often difficult as thera-
peutic proteins are very complex molecules. Because
of the different immune mechanisms, the value of an-
imals as predictive models is limited. A human pro-
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tein administered to animals will evoke a classical
immune response because of the exogenous character
of the protein, whereas patients treated with the same
protein will evoke a different immune response. Co-
agulation factor concentrates containing one or more
proteins are important therapeutic proteins in the
treatment and prevention of bleeding, and the use of
such concentrates are known to, at varying frequency,
trigger formation of antidrug antibodies that may also
be neutralizing (inhibitor formation). Inhibitor forma-
tion may occur both from the treatment with plasma-
derived and recombinant concentrates of FVIII or
FIX, but inhibitors to FVII are very unusual.1,2 For-
mation of neutralizing antibodies may have serious
consequences as in the case with recombinant ery-
thropoietin, where neutralizing antibodies arose be-
cause of the changes in the formulation and caused
pure red cell aplasia.3 To avoid unnecessary immuno-
genicity associated with manufacturing and formu-
lation processes, transgenic animal models could be
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of value to study the assessment of relative immuno-
genicity between products and differences in response
to drug delivery, such as a route of administration,
dosage, and frequencies as relative immunogenicity
would presumably be similar between humans and
nonhuman models.4
Immunotolerant animal models can be used to
study breaking of B-cell tolerance and drug-induced
antibody formation.5 Immunotolerance can be ob-
tained by neonatal tolerance induction or by using
transgenic mice expressing human proteins.6,7 Tol-
erance to FVIII has been induced by both intraperi-
toneal and intravenous injections of recombinant hu-
man FVIII to neonatal mice within 30 h after birth.
Treated mice were found to be tolerant to subsequent
injections of rFVIII in adult life, and the tolerance was
antigen specific.8,9 Neonatal tolerance induction has
also been induced in rats using recombinant human
FVII.10 Tolerance models using transgenic mice have
been developed for human IFN", IFN$, and FVIII,
among others.5,11–13 All of the models show tolerance
to the native human protein, whereas modifications of
the protein, for example, aggregation, had an impact
on immunogenicity. Thus transgenic mice offer an op-
portunity to study the mechanism of tolerance against
self-proteins as well as breakage of tolerance.7,14 This
has been demonstrated in several models with pro-
teins like INF", FVIII, and IFN$.5,11,13,15
In this paper, we present the development of a
unique triple-transgenic model, in which sequences
encoding the three human coagulation factors II (pro-
thrombin), VII, and X have been inserted into the
mouse genome making the mice triple transgenic, ex-
pressing all three human coagulation factors. This
triple-transgenic model has been tested in relative
immunogenicity studies using a combination of re-
combinant human FII, FVII, and FX.
MATERIAL AND METHODS
Animal Ethics
All animal experiments described in this paper have
been approved by the Animal Ethics Committee of
Gothenburg, Sweden.
Construction of Transgenic Mouse Strains
We have generated triple transgenic mice, which ex-
press the human coagulation factors II, VII, and X,
under the control of the cytomegalovirus (CMV) pro-
moter. The vector was designed to harbor all three
factors in tandem, although as separate expression
units. To minimize dysregulation and/or integration
effects, each expression unit was flanked by dou-
ble 1.2 kb insulator including CCCTC-Binding Fac-
tor (CTCF) binding sites, derived from the chicken
beta-globin locus.16 A Kozac sequence, GCCGCCACC,
Figure 1. Outline of the triple factor DNA construct in-
jected into fertilized eggs.
was placed −1 nt upstream of the ATG start codon of
each cDNA, and to stabilize the transcript, the bovine
growth hormone polyadenylation signal (bGH polyA)
was attached to the 3′ end of each transcription unit
(Fig. 1). The resulting transgenic DNA construct was
injected into the pronucleus of fertilized C57Bl/6NCrl
(Charles River Laboratories, Sulzfeld, Germany) eggs
and implanted into pseudo pregnant foster mothers.
Eight founder lines, A–H, were derived and two of
them, Line E; C57Bl/6-Tg(F2, F7, F10)EAztc, and Line
H; C57Bl/6-Tg(F2, F7, F10)HAztc, proved to express
all of the three human coagulation factors. Geno-
types were determined by PCR amplification of ge-
nomic DNA, derived from mouse ear biopsies, using
primers CMV F1; 5′-GTAGGCGTGTACGGTGGGAG-
3′, F2 Rev1; 5′-GCCCAGAACACATCCGTAGC-3′, F7
Rev1; 5′-AGCACTGCTCCTCCTTGCAC-3′, and F10
Rev1; 5′-CGTGGCAGAACTGGTCACAG-3′, in the
same PCR reaction giving rise to the following band
sizes: FII; 306 bp, FVII; 233 bp, and FX; 476 bp.
Verification of Human Coagulation Factor Expression
Transgenic mice were identified by genotyping using
PCR assays to detect sequences encoding human FII,
FVII, and FX. Expression of the human coagulation
factors was tested by three different ELISA assays
specific for human FII, FVII, and FX, respectively.
EDTA plasma samples were prepared from trans-
genic mice and wild-type littermates approximately
12 weeks of age. Plasma samples were stored frozen
at −70◦C or colder until analysis. Nunc Maxisorp
plates were coated with 100:L/well monoclonal an-
tibody directed to human FII (0.33–2:g/mL, prod-
uct P9115-04, Nordic Biosite, Ta¨by, Sweden), hu-
man FVII (2:g/mL product 2282, American Diag-
nostica, Pfungstadt, Germany) or human FX (2:g/
mL product GMA-520, Green Mountain Antibodies,
Burlington, Vermomt), diluted in carbonate coating
buffer (product C3041, Sigma Aldrich, Stockholm,
Sweden). Plates were coated overnight on a refriger-
ated shaker or wobbling table and then blocked with
100:L/well phosphate-buffered saline (PBS) contain-
ing 1% BSA (PBS/BSA) for 1 h at room temperature.
Plates were washed three times with PBS contain-
ing 0.05% (w/v) TWEEN 20 using a plate washer.
Samples were thawed at room temperature and di-
luted five times for the detection of human FII and
10 times for the detection of human FVII or human
FX in PBS/BSA. Standard curves were prepared in
PBS/BSA containing 10% pooled EDTA plasma from
wild-type mice (FVII and FX) or 20% pooled EDTA
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plasma from wild-type mice (FII). Standard range
for human FII was 5–250 ng/mL, for human FVII
2–64 ng/mL, and for human FX 5–160 ng/mL. After
addition of 50:L/well sample or standard, plates
were incubated on a wobbling table at room temper-
ature for 1.5 h and washed as before. Detection anti-
body diluted in PBS/BSA was added at 50:L/well. FII
detection antibody; ab9020 (Abcam, Cambridge, UK)
was diluted 1:2000–4000, FVII detection antibody;
SAFVII-AP (Enzyme Research Laboratories, South
Bend, Indiana) was diluted 1:4000, and FX detection
antibody; SAFX-AP (Enzyme Research Laboratories)
was diluted 1:2000. Plates were incubated for 1 h on
a wobbling table at room temperature and washed as
before. Mouse "-Sheep/Goat IgG conjugated to alka-
line phosphatase (Sigma Aldrich A8062) was diluted
1/4000 in PBS/BSA, 50:L was added to wells and
plates were incubated on a wobbling table at room
temperature for 1 h. After washing of the plates, as
before, 50:L/well of p-NPP solution (p-nitrophenyl
phosphate, Sigma Aldrich N27709) was added. After
suitable formation of yellow color, the reaction was
stopped by addition of 20:L/well 2 M sodium hydrox-
ide. Absorbance was read at 405 nm using Softmax
software. Transgenic mice from two lines, E and H,
were judged to produce detectable amounts of human
FII, FVII, and FX.
Mouse Immunization
Transgenic mice, approximately 12 weeks of age, from
lines E and H, were used in an immunization study
and wild-type littermates were included as controls.
Six wild-type and six transgenic mice from each line
and gender were included and dosed with 1 mg/kg,
each of recombinant human FII, FVII, and FX. The
mice were given a single subcutaneous injection just
below the neck every second week with a total of
four subcutaneous injections. The chosen dose level
and administration route were based on previous
knowledge on requirements for induction of antibody
production to autologous proteins using transgenic
mice.17 Plasma samples were taken predose and two
weeks after the last injection, and kept frozen at
−70◦C until analysis.
Compound and Formulation
The mice were injected with a combination of 1 mg/kg
of each recombinant human FII, FVII, and FX. The
protein solution was prepared in a 2 mM trisodium
citrate, 10 mM histidine, and 140 mM NaCl, pH 7.4
buffer containing <0.01 EU/mL endotoxin. The con-
centration of each test compound was determined by
UV spectroscopy, and the purity was assessed by size-
exclusion chromatography. To assure bioactivity, the
potency of the proteins was tested by coagulation fac-
tor assays for FII, FVII, and FX. FII potency was
tested by a prothrombinase assay (Kirchhof et al.,18
commercially available as Rox Prothrombin, Art No.
200040, Rossix, Mo¨lndal, Sweden). FVII potency was
tested by the Biophen FVII assay (Aniara, Mason,
Ohio, cat. No. A221304), and FX potency was tested
by the Biophen FX assay (Aniara, cat. No. A221705).
These assays were also used to estimate the concen-
tration of mouse coagulation factors II, FVII, and X
in mouse plasma.
Antidrug-Specific Ig Titers
Human FII-, FVII-, and FX-specific antibody titers
were measured in the plasma samples using ELISA.
FII, FVII, and FX were biotinylated with an EZ-
Link Sulfo-NHS-LC-biotinylation kit (Pierce, Rock-
ford, Illinois) according to vendor instruction, and the
biotinylated recombinant FII (1 mg/L), FVII (5 mg/L),
or FX (5 mg/L) was added to prewashed streptavidine-
coated plates (Nunc, Roskilde, Denmark). The plates
were incubated for 1 h at room temperature under
slow shaking (FII) or overnight at 4◦C (FVII and FX)
and thereafter washed and blocked. The plates were
washed and sample diluted in assay buffer was added
to each well and incubated for 2 h at room tempera-
ture. The plates were thereafter washed, and 100:L
of polyclonal rabbit "-mouse immunoglobulin anti-
body conjugated with horseradish peroxidase (Dako,
Copenhagen, Denmark) diluted in assay buffer was
added. After 1-h (FVII and FX) or 2-h (FII) incubation,
the plates were washed and EC-Blue R©-enhanced sub-
strate was added (Medicago, Uppsala, Sweden). After
5 min (FVII and FX) to 15 min (FII) at room temper-
ature, 0.5 M HCl was added to stop the reaction, and
the absorbance was read at 450 nm on a SpectraMax
Plus microplate reader (Molecular Devices, Sunny-
vale, California). Each plate contained one standard
curve with a range between 0.1 and 20 ng/mL (FII) or
0.5 and 1000 ng/mL (FVII and FX).
A screening was first performed where all samples
were diluted 1:100 in assay buffer and analyzed in
triplicate. Samples showing an optical density (OD)
value above the standard curve limit were further
diluted and analyzed in triplicates.
Statistical Analyses
To discriminate positive responses from background,
an upper negative limit of 95% for the cut-point was
used; a cutoff value from the predose samples was
calculated using OD values accordingly:
Cut − point = mean OD of all predose samples
+ 1.645 × SD
where 1.645 is the 95th percentile of the normal
distribution.19
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The cut-off was calculated to OD450 of 0.438 (FII),
0.103 (FVII), and 0.043 (FX), and values above this
cut-off point were regarded as positive.
Differences between pre- and postdose samples
were analyzed using OD values and a Paired t-test.
A value of p < 0.05 was considered to be statistically
significant.
Data from positive responders were generated as
concentrations (ng/mL) obtained from OD values cor-
related to a standard curve from the ELISA analyses.
Log-transformed data showed normal distribution
and was used to calculate possible significant differ-
ences in antidrug-specific antibody concentrations be-
tween the different groups using one-way ANOVA. A
value of p < 0.05 was considered to be statistically
significant.
RESULTS
We have successfully constructed triple-transgenic
mice expressing three human coagulation factors
by inserting a vector containing their encoding se-
quences and control sequences separated by beta-
globin insulator sequences into the mouse genome
(Fig. 1). The concentration of the three human co-
agulation factors in plasma samples from transgenic
mice was estimated to be approximately 10–50 ng/mL
and was similar for all three coagulation factors (data
not shown), indicating that the use of the insulator se-
quences had the desired effect. The transgenic expres-
sion levels of the coagulation factors were low com-
pared with murine endogenous levels; the murine en-
dogenous level of FII was measured to approximately
100:g/mL, the FVII level to approximately 1:g/mL,
and FX was measured to approximately 8:g/mL.
These murine endogenous levels are comparable to
human endogenous levels (data not shown). At the
achieved expression levels, the addition of the human
coagulation factors is therefore not likely to affect the
mouse coagulation system, and no adverse effects or
alteration of phenotype was observed for the trans-
genic mice. To test if transgenic mice differed from
wild-type mice in their ability to produce antibodies
to human FII, FVII, or FX, transgenic mice and wild-
type littermates were immunized with a mix of recom-
binant human FII, FVII, and FX, as described in “Ma-
terial and Methods.” Plasma samples were collected
before immunization and 2 weeks after the last ad-
ministration. Samples were analyzed for antibodies
to human coagulation factors, and the assay cut-point
for scoring a positive response was set in accordance
with regulatory recommendations (cut-point, 5% pos-
itive), as described in “Material and Methods.”17
In summary, there was a large difference in the
development of coagulation-factor-specific antibodies
between wild-type and transgenic animals following
the treatment. The transgenic animals responded
with lower levels of antibodies, even though signifi-
cance could not be reached in some groups because of
the large individual variation. For the different coag-
ulation factors, the results are given below.
Factor II
Pre- and postdosing samples were first compared. As
expected, wild-type male and female mice from both
line E (p < 0.0001 and p < 0.0001, respectively) and
H (p < 0.0001 and p < 0.0001, respectively) showed
a significant increase in antihuman FII-specific an-
tibodies following dosing. Transgenic male mice from
line E and line H and transgenic female mice from line
H did not develop any significant levels of human FII-
specific antibodies. However, transgenic female mice
from line E showed a significant increase in human
FII-specific antibodies, but the OD values were just
above the cut-point for positive responses (p = 0.03)
(Fig. 2, Table 1).
Group comparisons of postdose samples were done
between animals with antibody levels above cut-
point, and data showed that wild-type female mice
from both lines responded with significantly higher
levels of prothrombin-specific antibodies compared
with transgenic female mice from respective line. All
wild-type male mice from both lines responded with
high levels of prothrombin-specific antibodies follow-
ing treatment, whereas only one transgenic male
mouse from each line showed prothrombin-specific
antibody levels above the cut-off (Table 2).
Factor VII
All wild-type mice showed a high, significant increase
in anti-human FVII-specific antibodies when pre- and
postdosing samples were compared (E: p = 0.0001, p
< 0.0001 H: p < 0.0001, p < 0.0001). Transgenic male
mice from line E (p= 0.04) and transgenic female mice
from line H (p = 0.0001) also showed a significant
increase in drug-specific antibodies when comparing
pre- and postdose samples, but the responses were
very low, and the OD values were just above the cut-
point for positive responses. Transgenic male mice
from line H and transgenic female mice from line E
showed a small increase in FVII-specific antibodies,
but because of the large individual variation, there
was no significant difference (Fig. 3, Table 1).
When running a group comparison between groups
with antibody values above cut-point, wild-type male,
and female mice from both line E and H, as expected,
showed significant higher levels of FVII-specific an-
tibodies compared with respective transgenic strain
posttreatment. Wild-type female mice from both lines
and transgenic female mice from line E showed a
significantly higher level of FVII-specific antibodies
compared with respective male mice posttreatment
(Table 2).
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Figure 2. Human FII-specific antibody titers in pre- and posttreatment samples from wild-
type and transgenic animals from line E (a) and line H (b), measured by ELISA and expressed
as optical density (OD). Results were obtained from the screening assay where all samples were
diluted 1:100. One transgenic male mouse from line E died during the study. Mean OD values
are indicated by horizontal bars. Cut-off value was calculated to 0.438, values above this cutoff
point were regarded as positive. Wt, wild type; Tg, transgenic.
Factor X
Wild-type male mice from line H (p = 0.04) and fe-
male mice from both line E and H (E: p = 0.001
H: p < 0.0001) showed a significant increase in FX-
specific antibodies following dosing. The OD values
for the FX antibodies showed a higher degree of
variability among the individuals compared with the
prothrombin- and FVII-specific antibodies. Because of
this variation, the response from wild-type male mice
from line E did not show a significant response when
pre- and postdose samples were compared. Trans-
genic female mice from line E (p = 0.01) and trans-
genic male and female mice from line H (p= 0.003 and
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Table 1. Statistical Comparison of the Specific Antibody Response Between Samples
from Wild-Type (Wt) and Transgenic (Tg) Mice Before and After Treatment with a
Combination of Recombinant Human FII, FVII, and FX
FII FVII FX
Line E Line H Line E Line H Line E Line H
Wt Male <0.0001 <0.0001 0.0001 <0.0001 0.06 0.04
Female <0.0001 <0.0001 <0.0001 <0.0001 0.001 <0.0001
Tg Male 0.06 0.32 0.04 0.07 0.20 0.003
Female 0.03 0.13 0.13 0.0001 0.01 0.04
Differences between pre- and postdose samples were analyzed using OD values and a Paired t-test.
A value of p < 0.05 was considered to be statistically significant, marked with bold.
Table 2. Statistical Comparison of Values Above Cut-Point,
Between Genders Within Respective Line, and Between
Wild-Type (Wt) and Transgenic (Tg) Mice Following a
Combination Treatment of Recombinant Human FII, FVII, and
FX
Group 1 Group 2 p value
FII
Line E Wt female Line E Tg female p =0.001
Line H Wt female Line H Tg female p = 0.001
FVII
Line E Wt male Line E Tg male p = 0.001
Line E Wt female Line E Tg female p = 0.001
Line H Wt male Line H Tg male p = 0.001
Line H Wt female Line H Tg female p = 0.001
Line E Wt male Line E Wt female p = 0.01
Line E Tg male Line E Tg female p = 0.05
Line H Wt male Line H Wt female p = 0.001
FX
Line E Wt female Line E Tg female p = 0.01
Line H Wt male Line H Tg male p = 0.05
Line H Wt female Line H Tg female p = 0.001
Line H Wt male Line H Wt female p = 0.05
Log-transformed data were used to calculate significant differences in
antidrug-specific Ig concentrations between the different groups using
one-way ANOVA.
p = 0.04, respectively) showed a significant increase
in FX-specific antibodies following dosing. However,
the OD values were just above the cut-point for pos-
itive responses, and the biological significance is un-
clear (Fig. 4, Table 1).
Group comparisons between animals with re-
sponses above cut-point showed that wild-type female
mice from both lines and wild-type male mice from
line H, but not to line E because of large variation,
showed a significantly higher level of FX-specific an-
tibodies compared with respective transgenic strain
posttreatment. Wild-type female mice from line H
showed significantly higher levels of FX-specific an-
tibodies than wild-type male mice from line H and
wild-type female mice from line E (Table 2).
DISCUSSION
Today, it is not possible to predict immunogenicity
before entering clinical trials because it is difficult
to identify all factors responsible for induction of
immunogenicity.5 Thus, better preclinical models are
required and transgenic models could be one such
model system. Use of transgenic mouse model sys-
tems could, for instance, help evaluate different drug
modifications, as has been shown by van Helden
et al,20 where hFVIII transgenic mice were tolerant
to the native human protein but were able to mount
an antibody response to different modifications of the
protein. Similar models could be useful to identify
modifications that potentially break immune toler-
ance to the protein, as suggested by others.21
Our work was performed to generate a transgenic
mouse model to study immunological responses to hu-
man FII, FVII, and FX, given as single factors or in
combination. By designing a construct that harbors
all three coagulation factors, FII, FVII, and FX, in
tandem, although as separate expression units, these
immunological studies could be run using one single
mouse model. Another advantage of having the fac-
tors linked to each other in equimolar amounts is that
they will integrate into the same locus of the mouse
genome, which increases the likelihood of even ex-
pression levels. The breeding efficiency also improves,
as segregation of the factors is prevented, which dra-
matically reduces the numbers of animals needed and
simplifies genotyping of offspring as one PCR reaction
can amplify fragments from all three coagulation fac-
tor sequences simultaneously.
The two transgenic mouse strains obtained re-
sponded similarly when challenged with the human
coagulation factors II, VII, and X and may both be use-
ful in future studies. Although the obtained expres-
sion level was low judged by the amounts of human
coagulation factors detected in plasma samples, it was
sufficient to induce tolerance to human coagulation
factors II, VII, and X. However, the CMV promoter
used to control human FII, FVII, and FX expression
in the mice is likely to generate expression in many
tissues, which can contribute to inducing tolerance.
Coagulation factors are well conserved among
animal species and are often poorly immunogenic
if administered intravenously. We therefore chose
the subcutaneous route of administration as this
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Figure 3. Human FVII-specific antibody titers in pre- and posttreatment samples from wild-
type and transgenic animals from line E (a) and line H (b), measured by ELISA and expressed
as OD. Results were obtained from the screening assay where all samples were diluted 1:100.
One transgenic male mouse from line E died during the study. Mean OD values are indicated
by horizontal bars. Cut-off value was calculated to 0.103, values above this cutoff point were
regarded as positive. Wt, wild type; Tg, transgenic.
administration route is known to increase potential
immunogenicity, and less number of administrations
would be required. Wild-type mice responded strongly
with drug-specific antibodies following subcutaneous
injections with human FII, FVII, and FX. The trans-
genic mouse strains produced very low titers of drug-
specific antibodies, just above the assay cut-point,
demonstrating that a high degree of tolerance to the
human coagulation factors had been achieved. Com-
plete tolerance is not desired if the mouse strain
should be used to detect changes in immunogenicity
(i.e, as a result of manufacturing changes). We have
generated a human triple-transgenic mouse model,
and we have shown that the two transgenic lines
are tolerant when given a combination of recombi-
nant human FII, FVII, and FX. However, whether
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Figure 4. Human FX-specific antibody titers in pre- and posttreatment samples from wild
type and transgenic animals from line E (a) and line H (b), measured by ELISA and expressed
as optical density (OD). Results were obtained from the screening assay where all samples were
diluted 1:100. One transgenic male mouse from line E died during the study. Mean OD values
are indicated by horizontal bars. Cut-off value was calculated to 0.043, values above this cutoff
point were regarded as positive. Wt, wild type; Tg, transgenic.
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break of tolerance is achieved when injecting modified
versions of these coagulations factors, as a result
of modifications during manufacturing or because of
significant glycosylation changes, has not yet been
demonstrated. Future studies of interest would be to
test the tolerance of these transgenic strains using,
for instance, different drug products derived from dif-
ferent manufacturing processes.
In conclusion, we believe that transgenic mice may
be a valuable tool in assessing the risk of immuno-
genicity of a product, although results from animal
models are difficult to translate to humans and im-
munogenicity cannot be fully excluded. The success-
ful construction of mice expressing three different
proteins shows that combination products can also
be evaluated in immunotolerant animals. However,
one model cannot stand alone, and a combination
of experimental systems is required, involving not
only in vivo models but also advanced analytical
characterizations,22 and perhaps this could help to
improve the understanding of the mechanisms behind
immunogenicity and improve risk mitigation when
entering the clinic.
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